Thursday, Eli Lilly and Co (NYSE:LLY) released topline results from the QWINT-1 and QWINT-3 phase 3 trials evaluating once weekly insulin efsitora alfa (efsitora) in adults with type 2 diabetes.

The US Food and Drug Administration (FDA) has approved Sanofi’s Merilog (insulin-aspart-szjj), a biosimilar to Novolog ...

Eli Lilly’s big-selling insulin, Humalog, faces cut-price competition after the US regulator approved a biosimilar from Sanofi. Sanofi’s Admelog (insulin lispro) is approved in type 1 and type ...

While the issue has fallen from the headlines after several moves to cap the cost, some patients with diabetes still often ...

Drug company Eli Lilly announced it will cut the price of its insulin by 70 percent. How much will the drug cost and what does this mean for people with diabetes? Here's everything you need to ...

Grinding pancreases for insulin at Eli Lilly and Company, early 1930s ... introduced standardized strengths and developed new long-acting insulins. Although not identical to human insulin, animal ...

Merilog’s approval comes as the insulin space has over the past year suffered several setbacks, including strong calls for ...

Tandem Diabetes Care TNDM has achieved a significant milestone by gaining approval for the use of its t:slim X2 insulin pump with Eli Lilly’s ultra-rapid acting ... near and long term, Tandem ...

A settlement with drug-maker Novo Nordisk resolves the state's years-long litigation over insulin pricing and follows similar settlements already reached with Eli Lilly and Sanofi. “In 2018 ...

It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...

Eli Lilly’s big-selling insulin, Humalog, faces cut-price competition after the US regulator approved a biosimilar from Sanofi. Sanofi’s Admelog (insulin lispro) is approved in type 1 and type ...